Press Room

ViroGates announces first new ambulance study together with Nordic hospital partners starting May 2015

Denmark, April 13, 2015.

The Swedish Medical University Karolinska Institutet, Stockholm South General Hospital/Södersjukhuset, KI SÖS, and Helsinki University Central Hospital, HUCH, supported by ViroGates will initiate a pivotal ambulance study to explore the use of suPARnostic® in a new method for prehospital patient assessment.

In May 2015 an ambulance study aiming at testing 500 patients with suPARnostic® will start. The study will affect 65 ambulances in the Stockholm area and around 25 ambulances in the Helsinki area over a period of 6-9 months.

suPARnostic® can help acutely ill patients upon Emergency Room arrival
More than 10,000 emergency patients admitted to the acute care wards in Denmark, Austria and Finland have been tested with suPARnostic®. The publications confirm, that the biomarker suPAR is an independent marker of disease severity in heterogeneous patient cohorts, showing that suPARnostic® can help clinicians in the initial risk assessment and early triage of acutely ill patients upon Emergency Room arrival.

This new study will focus on the patient benefits of doing this evaluation prior to patient transport to the hospital.

Read the entire press release here.


Contact us

virogates logo2
Blokken 45

3460 Birkerød

Phone +45 21 13 13 36
Skype: virogates
CVR No.: 25734033

 in-2  tw-2